Early tumor shrinkage as a prognostic predictor in chemotherapy-naïve patients with locally advanced pancreatic cancer treated with modified FOLFIRINOX or gemcitabine plus nab-paclitaxel combination therapy: An exploratory analysis of JCOG1407.

导出 LinkOut

翻译打印收藏纠错

作者： Shun,Tezuka ^[1] ; Masato,Ozaka ^[2] ; Junji,Furuse ^[3] ; Masayuki,Yokoyama ^[4] ; Kohei,Uemura ^[4] ; Yusuke,Sano ^[4] ; Kohei,Nakachi ^[5] ; Hiroshi,Imaoka ^[6] ; Michiaki,Unno ^[7] ; Hirofumi,Shirakawa ^[5] ; Satoshi,Shimizu ^[8] ; Naoya,Kato ^[9] ; Yasushi,Kojima ^[10] ; Keiji,Sano ^[11] ; Satoshi,Kobayashi ^[3] ; Takeshi,Terashima ^[12] ; Chigusa,Morizane ^[13] ; Masafumi,Ikeda ^[6] ; Makoto,Ueno ^[3]

作者单位： Department of Gastroenterology, Kanagawa Cancer Center, Yokohama, Japan. Electronic address: tezuka-shun@kcch.jp. ^[1] Japanese Foundation for Cancer Research, Tokyo, Japan. ^[2] Department of Gastroenterology, Kanagawa Cancer Center, Yokohama, Japan. ^[3] JCOG Data Center/Operations Office, National Cancer Center Hospital, Tokyo, Japan. ^[4] Department of Medical Oncology, Tochigi Cancer Center, Utsunomiya, Japan. ^[5] Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, Kashiwa, Japan. ^[6] Department of Surgery, Tohoku University Graduate School of Medicine, Sendai, Japan. ^[7] Department of Gastroenterology, Saitama Cancer Center, Saitama, Japan. ^[8] Department of Gastroenterology, Chiba University, Chiba, Japan. ^[9] Department of Gastroenterology and Hepatology, National Center for Global Health and Medicine, Tokyo, Japan. ^[10] Department of Surgery, Teikyo University School of Medicine, Tokyo, Japan. ^[11] Department of Gastroenterology, Kanazawa University Hospital, Kanazawa, Japan. ^[12] Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Tokyo, Japan. ^[13]

关键词 Early tumor shrinkage Gemcitabine plus nab-paclitaxel Locally advanced pancreatic cancer Modified FOLFIRINOX